| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/29/2004 | US20040019916 In vivo homologous sequence targeting in eukaryotic cells |
| 01/29/2004 | US20040019195 Foreign nucleic acid molecule encoding multiple costimulatory molecules, such as B7-1 or B7-2 (antigents), intercellular adhesion molecules and leukocyte function associated antigen-3 |
| 01/29/2004 | US20040019188 Targeting through integrins |
| 01/29/2004 | US20040019181 Antimicrobial cationic peptides |
| 01/29/2004 | US20040019009 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule, specifically hybridizes with such nucleic acid, encoding IL-1 receptor-associated kinase-4; useful for treating cancer, infection and inflammation |
| 01/29/2004 | US20040019007 Intravascular delivery of non-viral nucleic acid |
| 01/29/2004 | US20040019002 Gene repair involving the induction of double-stranded DNA cleavage at a chromosomal target site |
| 01/29/2004 | US20040019001 Modulation gene expression |
| 01/29/2004 | US20040019000 Cellular uptake of immobilized oligomers |
| 01/29/2004 | US20040018977 Semaphorin-like proteins and methods of using same |
| 01/29/2004 | US20040018972 Autoimmune diseases; antiallergens; rheumatic diseases; antiinflammatory agents |
| 01/29/2004 | US20040018969 Genetic engineering; central nervous system disorders |
| 01/29/2004 | US20040018962 Drug delivery vehicles |
| 01/29/2004 | US20040018622 Therapy for skin disorders; genetic defects |
| 01/29/2004 | US20040018619 Central nervous system disorders; psychological disorders; therapy for brain tumors |
| 01/29/2004 | US20040018555 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 01/29/2004 | US20040018542 Phosphodiesterase enzymes |
| 01/29/2004 | US20040018529 Functional cloning of genes encoding proteins/enzymes involved in proteolytic cleavage |
| 01/29/2004 | US20040018525 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| 01/29/2004 | US20040018520 Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein |
| 01/29/2004 | US20040018514 Nucleotide sequence derived from Listeria inocua |
| 01/29/2004 | US20040018208 A part of the coding sequence of the middle glycoprotein of the hepatitis B virus, which has a dna sequence coding for at least one tumor epitope of a tumor antigen inserted |
| 01/29/2004 | US20040018180 Administering hematopoietic stem cells for activation of glands, to improve immune response to vaccines; leutinizing hormone-releasing hormone |
| 01/29/2004 | US20040018179 Bioadhesive directed somatic cell therapy |
| 01/29/2004 | US20040018178 Ablation of bone marrow and grafting genetic engineered isogeneic, allogeneic or xenogeneic cells, for prophylaxis of tumors or cancer |
| 01/29/2004 | US20040018173 Composition and method for the treatment and prevention of metastatic disorders |
| 01/29/2004 | DE19952982B4 Verfahren zur gerichteten Verpackung von molekularen Substanzen in Proteinhüllen Method for the directed packaging of molecular substances in protein shells |
| 01/29/2004 | DE10229379A1 EG-VEGF Rezeptor Antagonisten EG-VEGF receptor antagonists |
| 01/29/2004 | CA2493406A1 Gm-negative ehv-mutants without heterologous elements |
| 01/29/2004 | CA2493064A1 Tumor treating combinations, compositions and methods |
| 01/29/2004 | CA2493062A1 Tumor treating composition and methods |
| 01/29/2004 | CA2492905A1 Method of obtaining viable human liver cells, including hepatic stem/progenitor cells |
| 01/29/2004 | CA2492862A1 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 01/29/2004 | CA2492472A1 Use of urease for inhibiting cancer cell growth |
| 01/29/2004 | CA2492331A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 01/29/2004 | CA2467691A1 Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections |
| 01/28/2004 | EP1384784A1 Method for reversible inhibition of gene expression by modified ribonucleoproteins |
| 01/28/2004 | EP1384783A1 Novel maxizyme |
| 01/28/2004 | EP1384781A1 Methods for Modulating T-Cell Survival by Modulating BCL-XL Protein Level |
| 01/28/2004 | EP1384081A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
| 01/28/2004 | EP1383931A1 Nucleic acid vaccines for prevention of flavivirus infection |
| 01/28/2004 | EP1383927A2 New polynucleotides and polypeptides of the erythropoietin gene |
| 01/28/2004 | EP1383922A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 01/28/2004 | EP1383919A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/28/2004 | EP1383897A2 Self-containing lactococcus strain |
| 01/28/2004 | EP1383895A2 Polynucleotides and polypeptides of the ifnalpha-5 gene |
| 01/28/2004 | EP1383890A2 Mutants of desoxycytidine kinase having extended enzymatic activity |
| 01/28/2004 | EP1383884A2 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 01/28/2004 | EP1383883A2 Asthma-associated snps around microsatellite marker d2s308 and identification of human prolyl-oligopeptidase-dpp10 |
| 01/28/2004 | EP1383872A2 Genetically modified yt cell line and use thereof |
| 01/28/2004 | EP1383801A1 Antibodies against cancer |
| 01/28/2004 | EP1383793A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383745A1 Cationic amphiphiles as transfection vehicles |
| 01/28/2004 | EP1383541A1 Methods for delivering nucleic acid molecules into cells and assessment thereof |
| 01/28/2004 | EP1383540A2 Methods and pharmaceutical compositions for healing wounds |
| 01/28/2004 | EP1383536A1 Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit ccr5-tropic hiv-1 infection and replication |
| 01/28/2004 | EP1383535A2 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof |
| 01/28/2004 | EP1383530A2 Laminin 5, 13 and 14 and uses thereof |
| 01/28/2004 | EP1383528A2 Epitope sequences |
| 01/28/2004 | EP1383513A1 Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
| 01/28/2004 | EP1383481A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 01/28/2004 | EP1383480A2 Lipid-comprising drug delivery complexes and methods for their production |
| 01/28/2004 | EP1383460A2 Crf 2? ligands in combination therapy |
| 01/28/2004 | EP1383447A1 Stent-based delivery of statins to prevent restenosis |
| 01/28/2004 | EP1217990B1 Cationic dosper virosomes |
| 01/28/2004 | EP0763124B1 Method for introducing nucleic acid in higher eukaryotic cells |
| 01/28/2004 | EP0708637B1 Self-assembling polynucleotide delivery system comprising dendrimer polycations |
| 01/28/2004 | CN1471583A Packaging of positive-strand RNA virus replicon particles |
| 01/28/2004 | CN1471581A Human source gene guide sequence, gene carrier and gene expression method |
| 01/28/2004 | CN1471579A CRIPTO tumour polypeptide |
| 01/28/2004 | CN1471408A Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers |
| 01/28/2004 | CN1471407A Multifunctional nano device platform |
| 01/28/2004 | CN1470531A Target gene entraining system using histone as core sequence |
| 01/28/2004 | CN1470295A Electric perforating apparatus capable of expanding electrode interval |
| 01/27/2004 | US6683172 Composition for inhibiting inflammatory response comprising at least one nucleic acid molecule selected from specified sequences |
| 01/27/2004 | US6683170 Including peptides which selectively bound by targeted cell so that modified fiber protein is internalized by receptor-mediated endocytosis; trimerization |
| 01/27/2004 | US6683165 Human gene relating to respiratory diseases and obesity |
| 01/27/2004 | US6683155 Purified and isolated polypeptide comprising specified amino acid sequence; regulating degradation of extracellular matrix |
| 01/27/2004 | US6683059 Constructs for suppression of oncogenic transformation, tumorigenesis and metastasis |
| 01/27/2004 | US6683058 Methods for therapy of neurodegenerative disease of the brain |
| 01/27/2004 | US6683057 Suppressing g beta gamma signaling; reducing intimal hyper-plasia following vein grafting and restenosis following arterial injury |
| 01/27/2004 | US6682930 Triplex forming oligonucleotides and their use in anti-HBV |
| 01/27/2004 | US6682907 Lentivirus have the unique capacity among retroviruses of infecting differentiated non mitotic cells and represent viral candidates of interest for the development of novel vectors |
| 01/27/2004 | US6682743 Genetically engineered virus for use in the propagation of preferential cells |
| 01/27/2004 | US6682730 Transplants for myocardial scars |
| 01/27/2004 | US6682729 Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same |
| 01/27/2004 | US6682728 Efficient and selective adenoviral-mediated gene transfer into vascular neointima |
| 01/22/2004 | WO2004008147A2 Diagnosis and prevention of cancer cell invasion |
| 01/22/2004 | WO2004007770A2 Method for diagnosis of intestinal-type gastric tumors |
| 01/22/2004 | WO2004007764A2 Chromosome 3, 5 and 11 genes involved in premature canities |
| 01/22/2004 | WO2004007742A2 Chromosome 6 and 9 genes involved in premature canities |
| 01/22/2004 | WO2004007735A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 01/22/2004 | WO2004007734A1 Her-2/neu dna vaccine having anti-cancer activity |
| 01/22/2004 | WO2004007726A2 Brachyspira hyodysenteriae vaccine |
| 01/22/2004 | WO2004007723A2 Genes |
| 01/22/2004 | WO2004007718A2 Rna-interference by single-stranded rna molecules |
| 01/22/2004 | WO2004007698A1 Hemangioblast progenitor cells |
| 01/22/2004 | WO2004007678A2 Codon optimized synthetic plasmids |
| 01/22/2004 | WO2004007662A2 Polymer surfactants for gene therapy applications |